LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

NeoStrata Company, Inc.60 enrolled

Overview

The purpose of this study is to compare the safety and effectiveness of a new topical LCD solution and a commercially available calcipotriol (Vitamin D) cream in reducing the symptoms of plaque psoriasis and improving the quality of life in adults.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Chronic Plaque Psoriasis

Interventions

LCDDRUG

2 applications / day for 12 weeks

calcipotriolDRUG

2 applications / day for 12 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older * able and willing to provide written informed consent * diagnosed with chronic plaque psoriasis * 3% to 15% body surface area involved * in good general health Exclusion Criteria: * other current treatments for psoriasis * renal or liver dysfunction * pregnant or nursing

Locations (1)

Mass General Hospital: Clinical Unit for Research Trials in Skin

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Difference in percent reduction in Psoriasis Area and Severity Index (PASI) Scores between treatment arms

Time frame: 12 weeks of treatment

Secondary Outcomes

Changes in PLASI, PEASI, Physician Global Assessment (PGA), Pruritus, and Dermatology Life Quality Index (DLQI) Scores between treatment arms

Time frame: Week 12 and Week 18

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.